Citius Oncology grants Jonathan Peri 125K options

Available on EDGAR 11/13/2026 - 04:33 PM EST Accepted by SEC EDGAR 11/13/2026 - 04:31 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Citius Oncology, Inc. director Jonathan Peri was granted 125,000 stock options on November 12, 2026. The options have an exercise price of $0.5223 per share and expire on November 12, 2036. They vest in full on November 12, 2027, subject to his Continuous Service to the company or a Related Entity on that date.

Insider Trade Summary

Grant/Award: 125,000 shares

Grant/Award 1 txn

Insider Peri Jonathan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	125,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 125,000 options (Direct)

Footnotes (1)

1. F1. These options were granted on November 12, 2026. The options vest in full on November 12, 2027, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.

Key Figures

Stock options granted: 125,000 options Exercise price: $0.5223 per share Vesting date: November 12, 2027 +1 more

4 metrics

Stock options granted 125,000 options Granted to director Jonathan Peri on November 12, 2026

Exercise price $0.5223 per share Price to exercise the options

Vesting date November 12, 2027 Options vest in full, subject to the stated Continuous Service condition

Expiration date November 12, 2036 Expiration date of the options

Key Terms

Stock Option (Right to Buy), vest in full, Continuous Service

3 terms

Stock Option (Right to Buy) financial

"grant of Stock Option (Right to Buy)"

vest in full financial

"The options vest in full on November 12, 2027"

Continuous Service technical

"subject to the Reporting Person's Continuous Service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What options did CTOR director Jonathan Peri receive?

Jonathan Peri was granted 125,000 stock options on November 12, 2026, with an exercise price of $0.5223 per share. The options expire on November 12, 2036.

When do Jonathan Peri’s CTOR options vest?

The options vest in full on November 12, 2027, subject to his Continuous Service to Citius Oncology, Inc. or a Related Entity on that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peri Jonathan

(Last) (First) (Middle)

C/O CITIUS ONCOLOGY, INC.

11 COMMERCE DRIVE, 1ST FLOOR

(Street)

CRANFORD NEW JERSEY 07016

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CITIUS ONCOLOGY, INC. [ CTOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.5223	11/12/2026		A		125,000		(1)	11/12/2036	Common Stock	125,000	$0	125,000	D

Explanation of Responses:

1. These options were granted on November 12, 2026. The options vest in full on November 12, 2027, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.

	/s/ Alexander M. Donaldson, by Power of Attorney	11/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)